MONITORAGGIO DELLA FUNZIONE PIASTRINICA DURANTE TERAPIA CON TIENOPIRIDINE
|
|
|
- Randall Farmer
- 5 years ago
- Views:
Transcription
1 MONITORAGGIO DELLA FUNZIONE PIASTRINICA DURANTE TERAPIA CON TIENOPIRIDINE Rossella Marcucci 30 novembre 2013 CardioLucca 2013
2 CLOPIDOGREL: A MODEL FOR PERSONALIZED MEDICINE High on-treatment platelet reactivity
3 ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PCI WITH STENT IMPLANTATION DUAL ANTIPLATELET THERAPY ACUTE PHASE ISCHAEMIC EVENTS BLEEDING
4 Buonamici P, JACC 2007 n=804 RECLOSE TRIAL 10 micromol ADP LTA
5 Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12 month follow-up No RPR (PRU <240) n= 683 ACS patients CV death-free Survival RPR (PRU 240) VerifyNow P2Y12 log-rank test p= Time (months) HR=2.55 (95%CI ), p=0.034 Marcucci R et al, Circulation 2009
6 Iperattività piastrinica misurata con i comuni test di aggregazione piastrinica e prognosi: metanalisi
7 Impact of Platelet Reactivity on Clinical Outcomes After Percutaneous Coronary Intervention Somjot S. Brar et Al. JACC 2011
8 Prospective observational single center cohort study JAMA 2011;306(11):
9 STUDY FLOW n= 1789 n= 1525 n= % JAMA 2011;306(11):
10 Kaplan Meier survival curves for primary end point events Estimate risk 27.5% ( ) in HRPR group 14.5% ( ) in LRPR group 2 YRS FOLLOW-UP JAMA 2011;306(11):
11
12 CLOPIDOGREL: A MODEL FOR PERSONALIZED MEDICINE - Genetic Factors
13 C3435T Ile1145Ile ABCB1 Roles in clopidogrel activity of proteins with known genetic polymorphisms A672T Q192R PON1 CYP1A2 (35.8%) CYP2B6 (19.4%) CYP2C19 (44.9%) T744C H1/H2 P2Y12 T196C Leu59Pro ITGB3 CYP2B6 (32.9%) CYP2C9 (6.8%) CYP2C19 (20.6%) CYP3A4 (39.8%) Simon T et al, N Engl J Med 2009 Kazui M et al, Drug Metab Dispos 2009
14 Distribution of maximal platelet aggregation after different stimuli in the overall study population according to CYP2C19*2 genotypes 1419 ACS patients on dual antiplatelet therapy undergoing percutaneous coronary intervention (PCI) and stent implantation CYP2C19*2 genotypes *1/*1 *1/*2 *2/*2 p (overall) *1/*2+*2/*2 p (vs. *1/*1) Subjects N (%) 974 (68.6%) 405 (28.6%) 40 (2.8%) 445 (31.4%) Aggregation according to stimulus % ADP (2µM) ADP (10µM) AA (0.5 mg/ml) 26 (1-100) 32 (1-94)* 41 (5-84)* < (1-94) < (1-100) 54 (2-100) * 62 (26-100)*# < (2-100) < (1-100) 12 (1-100) 14 (5-85) (1-100) *p< vs *1/*1; p=0.028 vs *1/*2; #p=0.015 vs *1/*2; Giusti B et al, Pharmacogenetics and Genomics 2007; 17(12):
15 Cardiovascular death, MI or ischemic stroke JAMA 2010
16 Stent Thrombosis JAMA 2010
17
18 JAMA, 2011 ELEVATE TIMI 56 Conclusion Among patients with stable cardiovascular disease, tripling the maintenance dose of clopidogrel to 225 mg daily in CYP2C19*2 heterozygotes achieved levels of platelet reactivity similar to that seen with the standard 75-mg dose in noncarriers; in contrast, for CYP2C19*2 homozygotes, doses as high as 300 mg daily did not result in comparable degrees of platelet inhibition.
19 CLOPIDOGREL: A MODEL FOR PERSONALIZED MEDICINE - Genetic Factors -Acquired Factors: clinical characteristics
20 HIGH ON TREATMENT PLATELET REACTIVITY BY ADP AND INCREASED RISK OF MACE IN GOOD CLOPIDOGREL METABOLIZERS: BEYOND PHARMACOGENETIC APPROACH n= 892 patients NON carriers of CYP2C19*2 polymorphism 12 month follow-up Marcucci R et al, Platelets 2012
21 Erythrocyte deformability TRANSIENT Acute phase Platelet turn-over Inflammation Reticulated platelets ADAMTS-13 activity High on-treatment platelet reactivity Compliance Drug interactions CYP2C19 polymorphism DRUG RESISTANCE PERMANENT Diabetes Chronic Systolic function Age, sex PERSISTENT
22 Multivariate logistic regression analysis on risk of having RPR * IPF vs. AA-RPR 1.77 ( ) p=0.03 H-IPF vs. AA-RPR 1.62 ( ) p=0.03 IPF vs. ADP-RPR H-IPF vs. ADP-RPR 1.76 ( ) 1.74 ( ) p=0.02 p= OR 95%CI *Adjusted for age, gender, family history of CAD, smoking habit,hypertension, diabetes, dyslipidemia, hematocrit, STEMI/NSTEMI, use of GpIIb/IIIa inhibitors and platelet count 3 Cesari et al, Thromb Haemost
23 CYTOCHEMOKINE LEVELS ACCORDING TO PLATELET REACTIVITY by 10 µm ADP in ACS Gori et al., Atherosclerosis 2009 p<0.01 IL-6 p<0.001 IP-10 p<0.05 IL-4 p<0.05 IL-10
24 High on-thienopyridine platelet reactivity in elderly coronary patients:the SENIOR-PLATELET study Silvain L, EHJ 2011 Rate of high platelet reactivity (PRU. 235) (Figure 2A) and mean inhibition (%) (Figure 2B) in patients treated with an MD of 75 mg of clopidogrel according to decades of age identified with the VN-P2Y12 assay. Mean inhibition corresponds to the ratio PRU iso-trap/pru ADP-PGE. Asterisks indicate P, 0.05 with Kruskall Wallis test for multiple comparison.
25 Clinical and laboratory characteristics according to platelet reactivity by 10 microm ADP-PA ACS patients (n=386) Elective PCI (n=482) With RPR (n=99) Without RPR (n=287) p With RPR (n=93) Without RPR (n=389) P Age 68.3( ) 68.3( ) ns 68.4( ) 67.7( ) ns Sex (M/F) 69/30 206/81 ns 70/23 294/95 ns Smoking habit (%) ns ns Hypertension (%) ns ns Diabetes (%) Dyslipidemia (%) ns PAD (%) ns ns AF(%) ns ns Previous use of clopidogrel (%) Ejection Fraction 40% (%) Leukocytes (x 10 9 /L) ns ( ) ( ) ( ) 7244 ( ).0001 ESR (mm/h) 45.7 ( ) 29.5 ( ) ( ) 18.2 ( ).0001 Marcucci R et al, Atherosclerosis 2007
26 CLOPIDOGREL: A MODEL FOR PERSONALIZED MEDICINE - Genetic Factors -Acquired Factors: Drug-drug interactions
27 ORs for MACE according to PPI use (n=46,037) Hulot et al, JACC 2010
28 CLOPIDOGREL: HOW TO OVERCOME HIGH PLATELET REACTIVITY
29 Iperattività piastrinica e tailored antiplatelets therapy I GRANDI TRIAL Standard-vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention. Matthew J. Price et Al. JAMA, March 16, 2011
30 CV Events and Post-PCI PRU In Patients With High and Not High Reactivity Treated With Clopidogrel 75-mg Daily 500 PRU hrs post-pci Red dots: patients with CV death, MI, or ST 230 PRU N=1105 N= 586 ITT population High Residual Reactivity Not High Residual Reactivity
31 Collet JP et al., N Engl J Med 201 Pts scheduled to undergo DES implantation EXCLUSION criteria: primary PCI for STEMI planned use of GpIIb/IIIa inhib.
32 Collet JP et al., N Engl J Med 2012 Death, MI, stroke/tia, Urgent revascularization, Stent thrombosis
33 Collet JP et al., N Engl J Med /1213 loading dose and the others?
34 Collet JP et al., N Engl J Med 2012
35 Collet JP et al., N Engl J Med 2012
36
37 Whole cohort Non carriers of CYP2C19*2 Carriers of CYP2C19*2 Roberts, Lancet 2012
38 Roberts, Lancet 2012
39 Roberts, Lancet 2012 Point of care genetic testing after PCI can be done effectively at the bedside and treatment of identified CYP2C19*2 carriers with prasugrel can reduce high on-treatment platelet reactivity
40 GIANT STUDY Clopidogrel Genotyping for Antiplatelet Guidance in MI Stenting: Maybe Reduced Ischemic Risk November 06, 2013 TCT In the prospective GIANT trial with 1445 patients, it was discretionary whether clinicians raised the clopidogrel dosage or switched thienopyridine agents based on the assay results, which they had in hand within 48 hours after stenting. Such changes were made in 86% of the 316 who tested positive for the LOF genotype, a group known to be at increased ischemic risk on standard clopidogrelcontaining antiplatelet therapy after stenting.
41 GIANT STUDY Clopidogrel Genotyping for Antiplatelet Guidance in MI Stenting: Maybe Reduced Ischemic Risk November 06, 2013 TCT Among those 272 patients with assay-guided antiplatelet changes, the one-year composite risk of death, MI, or stent thrombosis closely matched that of patients lacking the high-risk genotype Of note, the composite end point was about five times higher for the remaining 14% of LOF-genotype patients whose antiplatelet therapy wasn't changed based the assay End point Normal n=1118 LOF, treatment is adjusted, n=272 LOF, treatment is not adjusted, n=55 Primary * 15.6
42 TRANSIENT Acute phase High on-treatment platelet reactivity
43 NATURAL HISTORY OF HPR BY ADP IN ACS PATIENTS AMI FLORENCE STUDY
44 Atherosclerosis 2013
45 Atherosclerosis 2013
46 The next FUTURE. - Prasugrel / Ticagrelor for ALL patients? - Prasugrel/Ticagrelor: duration of therapy?
47 NSTEMI 2011
48 NSTEMI 2011
49 2012
50
51 What about costs? In Italy: CLOPIDOGREL (generic drug) PLAVIX PRASUGREL 1 year 0.57 E/cp 205E 0.65 E/cp 234E 2.57 E/cp 925E TICAGRELOR 1.80 E/cp 648E
52 CLOPIDOGREL HYDROGEN SULFATE
53 n= 21 HEALTHY volunteers Clin Res Cardiol 2009
54 n=150 pts CHS= Clopidogrel Hydrogensulfate CB= clopidogrel besylate Thromb Res 2011
55
56 CLOPIDOGREL BASE (n=741) CLOPIDOGREL HYDROGENSULFATE (n=838) Age (yrs) 72±12 71± Sex (M/F) 521/ / Hypertension, n (%) 510 (68.8) 570 (68) Diabetes, n (%) 163 (21.9) 192 (22.9) Smoking, n (%) 373 (50.3) 415 (495) Dyslipidemia, n (%) 290 (39.1) 330 (39.3) STEMI/NSTEMI 363/ / HPR by ADP n (%) 314 (42.2) 213 (25.4) < p 10 µm/l ADP-PA 58%±20% 52%±19% < mm arachidonic acid-pa 18%±7% 17%±9% µg/ml collagen-pa 36.7%±15.2% 33.5%±16.6% <0.001 Marcucci R et al. JACC 2013
57 Oct. Nov. Dec. Jan. Feb. Mar. = Clopidogrel hydrogensulfate = Clopidogrel base /166 (27%) /144 (40%) P< /144 (30%) P< /126 (42%) /133 (29%) P= /135 (38%) /124 (30%) P< /114 (44%) /130 (24%) P< /99 (44%) /141 (13%) P< /123 (45%) ADP (%) 56.7± ± ± ± ± ± ± ± ± ± ± ±20.8 TOTAL 213/838 (25.4 %) 314/741 (42.4%) P< ± ± (%) Marcucci R et al. JACC 2013
58 Marcucci R et al. JACC 2013 Italian Generic Clopidogrel Worse Than Brand Name at Suppressing Platelets Acompany press releasereports that Dr. Reddy s launched bioequivalent generic clopidogrel tablets, 75 mg and 300 mg, in the United States on May 18, The US version appears to be clopidogrel bisulphate, and not the base form. In June 2009, the EMEA gave the go-ahead to 6 generic versions of clopidogrel bisulfate and the drug is now available in several European countries. On June 2, 2010, the EMEA approved the generic version clopidogrel base, stating that 75-mg tablets possess adequate quality and benefit/risk ratio and are comparable to the reference clopidogrel product.
59
60 The next FUTURE. - Prasugrel / Ticagrelor for ALL patients? - Prasugrel/Ticagrelor: duration of therapy?
61 CHRONIC PHASE ISCHAEMIC EVENTS BLEEDING
62 Consensus and Update on the Definition of On-Treatment Platelet Reactivity to ADP Associated with Ischemia and BLEEDING Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, Kirtane A, Siller-Matula J, Mahla E, Becker RC, Bhatt DL, Waksman R, Rao SV, Alexopoulos D, Marcucci R, Reny JL, Trenk D, Sibbing D, Gurbel PA. J Am Coll Cardiol Sep 26. doi:pii: S (13)
63
64 Sibbing D et al, J Thromb Haemost 2010
65 Prospective Evaluation of On-Clopidogrel Platelet Reactivity Over Time in PatientsTreated With Percutaneous Coronary Intervention Relationship With Gene Polymorphisms and Clinical Outcome Campo G, JACC 2011
66 Residual Platelet Reactivity, Bleedings, and Adherence to Treatment in Patients Having Coronary Stent Implantation Treated With Prasugrel Parodi et al., AJC Oct 2011 Multivariate analysis LTA 10 µm ADP < 40% : 96/298 (32%) OR FOR BLEEDING EVENTS Female gender: OR= 2.2 ( ), p=0.029 Low RPR: OR= 0.91 ( ), p=0.001
67 From clopidogrel through drug resistance to NEW antiplatelets from MONITORING antiplatelet therapy to the identification of a risk marker ON dual antiplatelets.toward a tailored antiplatelet treatment based on symptoms, clinical and procedural characteristics and platelet function testing..
and Ticagrelor Professor of Medicine (Cardiology), Georgetown University Associate Director, Division of Cardiology, Washington Hospital Center
Role of Genotyping and Point-of-Care of Testing in Clopidogrel, Prasugrel, and Ticagrelor Ron Waksman, MD Ron Waksman, MD Professor of Medicine (Cardiology), Georgetown University Associate Director, Division
ΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ. Εξατοµικευµένη αντιαιµοπεταλιακή αγωγή. Ποιο είναι το µέλλον?
ΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ ΕΡΕΥΝΗΤΙΚΟ ΚΕΝΤΡΟ ΑΘΗΡΟΘΡΟΜΒΩΣΗΣ Εξατοµικευµένη αντιαιµοπεταλιακή αγωγή. Ποιο είναι το µέλλον? Αλέξανδρος Δ. Τσελέπης, MD, PhD Καθηγητής Βιοχηµείας - Κλινικής Χηµείας Disclosures
New insights in stent thrombosis: Platelet function monitoring. Franz-Josef Neumann Herz-Zentrum Bad Krozingen
New insights in stent thrombosis: Platelet function monitoring Franz-Josef Neumann Herz-Zentrum Bad Krozingen New insights in stent thrombosis: Platelet function monitoring Variability of residual platelet
Do We Need Platelet Function Assays?
Do We Need Platelet Function Assays? Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic, La Jolla, CA The Antiplatelet Effect of Clopidogrel Varies Widely Among Individuals
Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management
Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis Disclosures
Speaker s name: Thomas Cuisset, MD, PhD
Speaker s name: Thomas Cuisset, MD, PhD X I have the following potential conflicts of interest to report: x Consulting: Daiichi Sankyo, Eli Lilly Employment in industry Stockholder of a healthcare company
Platelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary
Platelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary Dániel Aradi MD PhD Interventional Cardiologist Assistant professor
Clopidogrel Response Variability and Platelet Function Testing: Should Routine Practice Be Changed in Interventional Cardiology?
Clopidogrel Response Variability and Platelet Function Testing: Should Routine Practice Be Changed in Interventional Cardiology? Matthew J. Price MD, FACC Director, Cardiac Catheterization Laboratory Scripps
ACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Optimising Crossover from Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome [CAPITAL OPTI-CROSS] Monique Conway, PharmD, BCPS PGY-2 Cardiology Pharmacy
What hematologists should know about VerifyNow
What hematologists should know about VerifyNow Hematology fellows conference 12/13/2013 Presenter: Christina Fitzmaurice, MD, MPH Discussant: Daniel Sabath, MD, PhD HMC consult patient 54 yo woman admitted
Clopidogrel vs New Antiplatelet Therapy (Prasugrel) Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany
Clopidogrel vs New Antiplatelet Therapy () Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany Seoul, April 3, 21 Dual Antiplatelet Therapy for Stenting MACE, % 12 1 8 6 In
Point-of-Care Genetic Testing for Tailored Anti-Platelet Therapy Ready for Prime Time?
Point-of-Care Genetic Testing for Tailored Anti-Platelet Therapy Ready for Prime Time? Robert G. Wilkins, M.D., F.A.C.C., F.S.V.M New Cardiovascular Horizons May 29, 2015 No Disclosures Dual Anti-Platelet
Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor
Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor Leonardo Bolognese Cardiovascular Department, Arezzo, Italy Platelet Reactivity in Patients with STEMI Undergoing Primary PCI Campo G et
Session Objectives. Clopidogrel Resistance. Clopidogrel (Plavix )
Session Objectives New Antithrombotics and Real Time Genetic Testing: Their Role in the Vascular Patient Margaret C. Fang, MD, MPH Associate Professor of Medicine Division of Hospital Medicine Medical
Δοκιμασίες λειτουργικότητας αιμοπεταλίων και PCI
Δοκιμασίες λειτουργικότητας αιμοπεταλίων και PCI Ομάδες Εργασίας Φεβρουάριος 2016 Ξανθοπούλου Ιωάννα Καρδιολόγος Επιμ Β ΠΓΝΠατρών Nothing to disclose Platelet function testing (PFT) is helpful in identifying
Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
Clopidogrel Use in ACS and PCI: Clinical Trial Update
Clopidogrel Use in ACS and PCI: Clinical Trial Update Matthew J. Price MD Director, Cardiac Catheterization Laboratory, Scripps Clinic, La Jolla, CA Assistant Professor, Scripps Translational Science Institute
Disclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
Μιχάλης Χαμηλός, MD, PhD, FESC
Αντίσταση στα αντιαιμοπεταλιακά. Πως μετράται, πότε πρέπει να εκτιμάται, και πως αντιμετωπίζεται Μιχάλης Χαμηλός, MD, PhD, FESC Πανεπιστημιακό Νοσοκομείο Ηαρκλείου Disclosures Speakers Honoraria: Astra
Pharmacogenomics with Clopidogrel: Does One Size Fit All?
Pharmacogenomics with Clopidogrel: Does One Size Fit All? Leah A. Sabato, PharmD PGY-1 Pharmacy Practice Resident UC Health - University of Cincinnati Medical Center leah.sabato@uchealth.com April 2015
Personalized Antiplatelet Therapy: State of the Art
Personalized Antiplatelet Therapy: State of the Art Paul A. Gurbel, M.D. Sinai Center for Thrombosis Research Associate Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland,
Which drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
תרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון מרכז רפואי רבין
תרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון בי""י מרכז רפואי רבין 1. Why should clopidogrel be replaced? 2. Prasugrel 3. Ticagrelor 4. Conclusions CURE TRIAL ACS pts 20 % reduction
The Pharmacogenetics of Clopidogrel
The Pharmacogenetics of Clopidogrel CANNeCTIN Cutting-Edge Pharmacogenetics Symposium May 22, 2009 Marc S. Sabatine, MD, MPH Investigator, TIMI Study Group Associate Physician, Cardiovascular Division,
INDIVIDUALIZED MEDICINE
CENTER FOR INDIVIDUALIZED MEDICINE Clopidogrel Pharmacogenetics Can We Impact Clinical Practice? Michael E. Farkouh, MD, MSc Peter Munk Cardiac Centre University of Toronto Naveen Pereira MD Mayo Clinic
IMMATURE PLATELETS CLINICAL USE
HAEMATOLOGY FEBRUARY 217 WHITE PAPER IMMATURE PLATELETS CLINICAL USE Identifying poor antiplatelet drug response and its risks early on Platelets are important cells for repairing endothelial lesions,
Why and How Should We Switch Clopidogrel to Prasugrel?
Case Presentation Why and How Should We Switch Clopidogrel to Prasugrel? Shaul Atar Western Galilee Medical Center Nahariya, ISRAEL Case Description A 67 Y. Old Pt. admitted to IM with anginal CP. DM,
Platelet Function Testing: Which Test, and How to Apply? - Current Limitations and Future Perspectives - Young-Hoon Jeong, M.D., Ph.D.
Platelet Function Testing: Which Test, and How to Apply? - Current Limitations and Future Perspectives - Young-Hoon Jeong, M.D., Ph.D. Director, Clinical Trial Center, Gyeongsang National University Hospital;
Upcoming Evidence and Practice of Optimal Antiplatelet Therapy in DES Era?
Upcoming Evidence and Practice of ptimal Antiplatelet Therapy in DES Era? Polymorphism in Metabolism of Clopidogrel and Its Clinical Implications and Management Alexandra Lansky MD Columbia University
Dual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
Αντιαιμοπεταλιακη αγωγη (ποια, πο τε και για πο σο)
Αντιαιμοπεταλιακη αγωγη (ποια, πο τε και για πο σο) Dimitrios Alexopoulos, MD, FESC, FACC Cardiology Department, Patras University Hospital, Patras, Rio, Greece. Patras University Hospital I, Dimitrios
A PRAGMATIC RANDOMIZED TRIAL OF CYP2C19 GENOTYPING IMPLEMENTATION FOLLOWING PERCUTANEOUS CORONARY INTERVENTION (PCI)
A PRAGMATIC RANDOMIZED TRIAL OF CYP2C19 GENOTYPING IMPLEMENTATION FOLLOWING PERCUTANEOUS CORONARY INTERVENTION (PCI) Sony Tuteja, PharmD, MS Twitter @sony_tuteja Perelman School of Medicine at the University
Genetic Causes of Clopidogrel Nonresponsiveness: Which Ones Really Count?
Genetic Causes of Clopidogrel Nonresponsiveness: Which Ones Really Count? Kathryn M. Momary, Pharm.D., Michael P. Dorsch, Pharm.D., M.S., and Eric R. Bates, M.D. Clopidogrel decreases the morbidity and
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
Optimal Duration and Dose of Antiplatelet Therapy after PCI
Optimal Duration and Dose of Antiplatelet Therapy after PCI Donghoon Choi, MD, PhD Severance Cardiovascular Center Yonsei University College of Medicine Optimal Duration of Antiplatelet Therapy after PCI
Antiplatelet agents treatment
Session III Comprehensive management of diabetic patients Antiplatelet agents treatment Chonnam National University Hospital Department of Internal Medicine Dong-Hyeok Cho CONTENTS Introduction Prothrombotic
When and how to combine antiplatelet agents and anticoagulant?
When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation
Is Cangrelor hype or hope in STEMI primary PCI?
Is Cangrelor hype or hope in STEMI primary PCI? ARUN KALYANASUNDARAM MD, MPH, FSCAI HOPE Issues with platelet inhibition in STEMI Delayed onset In acute settings, achieving the expected antiplatelet effect
Joint Meeting of Coronary Revascularization 8 th to 9 th December 2017
B Joint Meeting of Coronary Revascularization 8 th to 9 th December 2017 A Novel Clinical Application Combining Genotyping and Platetlet Function Testing In Patients With Acs - A Case Series Shirley Tan
DECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network
Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs
Ticagrelor vs prasugrel in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention
DISCLOSURES: NONE Ticagrelor vs prasugrel in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention I. Xanthopoulou, KC. Theodoropoulos, G. Kassimis, V.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
Thrombosis Research active studies
Thrombosis Research active studies A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients With Coronary Artery Disease Undergoing PCI With CYP2C19 Loss-of-function Genotypes: A Feasibility
Learning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
Κωνσταντίνος Π. Τούτουζας Επ. Καθηγηηής Καρδιολογίας. A Πανεπιζηημιακή Καρδιολογική Κλινική, Ιπποκράηειο Νοζοκομείο
Κωνσταντίνος Π. Τούτουζας Επ. Καθηγηηής Καρδιολογίας A Πανεπιζηημιακή Καρδιολογική Κλινική, Ιπποκράηειο Νοζοκομείο Europe* 2001 2011 Incident MI 291,100 327,700 US 2001 2011 Incident MI 405,100 485,200
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization
Prasugrel: Son of Clopidogrel or Distant Cousin? Disclosures. Objectives
Prasugrel: Son of Clopidogrel or Distant Cousin? By John J. Bon, Pharm.D., BCPS Lead Clinical Pharmacist, Critical Care Summa Health System Disclosures I have no actual or potential conflict of interest
3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
Cytochrome P450 interactions
Cytochrome P450 interactions Learning objectives After completing this activity, pharmacists should be able to: Explain the mechanism of action of clopidogrel-ppi interaction Assess the risks and benefits
The Role of Triple Antiplatelet Therapy in Patients with High Risk
TAPT: Adjunctive Cilostazol to Aspirin and Clopidogrel The Role of Triple Antiplatelet Therapy in Patients with High Risk Young-Hoon Jeong, MD, PhD Department of Internal Medicine, Gyeongsang National
Controversies in PCI A young cardiologist s perspective
Controversies in PCI A young cardiologist s perspective Antiplatelet Tx, PLT function monitoring should be mandatory CONTRA M. Valgimigli, MD, PhD Ferrara, Italy Euro-PCR Session @ ESC August 30th 2010,
Cilostazol: Triple Benefits More is Better!
Cilostazol: Triple Benefits More is Better! Matthew J. Price, MD Director, Cardiac Catheterization Laboratory Scripps Clinic, La Jolla, CA Assistant Professor, Scripps Translational Science Institute,
Switching antiplatelet regimens: alternatives to clopidogrel in STEMI patients
Patras University Hospital Switching antiplatelet regimens: alternatives to clopidogrel in STEMI patients Dimitrios Alexopoulos, MD, FESC, FACC Professor of Cardiology Patras University Hospital Greece
Optimal lenght of DAPT in different clinical scenarios
Optimal lenght of DAPT in different clinical scenarios After PCI with DES in the light of recent and ongoing studies Dr Grégoire Rangé / CH Chartres / France DAPT duration depend on the evolution of risk
On admission Acute extensive anterior STEMI
Mr B 52 years old male Smoker No prior known CAD Presents with 1 hour intermittent crushing retrosternal chest pain Transferred by MICU directly to CCU (ASA, Heparin) On admission Intense pain, diaphoretic
Impact of CYP2C19 and ABCB1 SNPs on outcomes with ticagrelor versus clopidogrel in acute coronary syndromes: a PLATO genetic substudy
Impact of CYP2C19 and ABCB1 SNPs on outcomes with ticagrelor versus clopidogrel in acute coronary syndromes: a PLATO genetic substudy Lars Wallentin, Stefan James, Robert F Storey, Martin Armstrong, Bryan
GENNARO SARDELLA MD, FACC,FESC
PhaRmacodynamic Effects of Switching therapy in PCI patients with high on Treatment platelet reactivity and genotype variation: high Clopidogrel dose versus Prasugrel (RESET GENE Study). (ClinicalTrials.gov
Clopidogrel is the second-leading drug sold worldwide,
CONTROVERSIES IN CARDIOVASCULAR MEDICINE Do Platelet Function Testing and Genotyping Improve Outcome in Patients Treated With Antithrombotic Agents? The Role of Platelet Reactivity and Genotype Testing
Dual Antiplatelet duration in ACS: too long or too short?
Dual Antiplatelet duration in ACS: too long or too short? Leonardo Bolognese, MD, FESC, FACC Cardiovascular Department, Arezzo, Italy Paradigm Shift the ideal duration of DAPT: a moving target Early (stent-related)
The Korean Society of Cardiology COI Disclosure
The Korean Society of Cardiology COI Disclosure Name of First Author: Yongwhi Park The authors have no financial conflicts of interest to disclose concerning the presentation 2017 Annual Spring Scientific
L Bonello, L Camoin-Jau, S Arques, C Boyer, D Panagides, O Wittenberg, MC Siméoni, P Barragan, F Dignat-George, F Paganelli.
Adjusted Clopidogrel Loading Doses According to VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel low response: A Multicentre Randomized Prospective
P2Y 12 blockade. To load or not to load before the cath lab?
UPDATE ON ANTITHROMBOTICS IN ACUTE CORONARY SYNDROMES P2Y 12 blockade. To load or not to load before the cath lab? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria,
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
Dual Oral Antiplatelet Therapy for ACS: Improving Standards of Care to Optimize Outcomes
Agenda Welcome and Introduction Pathophysiology of ACS Is Aspirin Enough? Overview of Antiplatelet Agents Clopidogrel Prasugrel Ticagrelor New Guideline Recommendations for Dual Antiplatelet Therapy in
Opinion statement. Coronary Artery Disease (PH Stone, Section Editor)
Current Treatment Options in Cardiovascular Medicine (2012) 14:24 38 DOI 10.1007/s11936-011-0157-2 Coronary Artery Disease (PH Stone, Section Editor) Optimal Management of Antiplatelet Therapy and Proton
Updated and Guideline Based Treatment of Patients with STEMI
Updated and Guideline Based Treatment of Patients with STEMI Eli I. Lev, MD Director, Cardiac Catheterization Laboratory Hasharon Hospital, Rabin Medical Center Associate Professor of Cardiology Tel-Aviv
July ACCP Cardiology PRN Journal Club 7/23/2018
July ACCP Cardiology PRN Journal Club 7/23/2018 Dr. Michael Plazak Dr. Michael Plazak is a PGY2 Cardiology Pharmacy Resident at the University of Maryland School of Pharmacy. He graduated from the University
Προβληματισμοι στην χρηση αντιαιμοπεταλιακων στα οξέα ισχαιμικά σύνδρομα
Α ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΚΑΙ ΟΜΩΝΥΜΟ ΕΡΓΑΣΤΗΡΙΟ ΙΑΤΡΙΚΗ ΣΧΟΛΗ ΠΑΝΕΠΙΣΤΗΜΙΟΥ ΑΘΗΝΩΝ ΙΠΠΟΚΡΑΤΕΙΟ ΓΕΝΙΚΟ ΝΟΣΟΚΟΜΕΙΟ ΑΘΗΝΩΝ Διευθυντής: Καθηγητής ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Προβληματισμοι στην χρηση αντιαιμοπεταλιακων
DECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST How to manage antiplatelet treatment in patients with diabetes in acute coronary syndrome Lars Wallentin Professor of Cardiology, Chief Researcher Cardiovascular Science
Στεφανιαίος ασθενής με μη βαλβιδική Κολπική Μαρμαρυγή - Νέες στρατηγικές
4 ο ΠΑΝΕΛΛΗΝΙΟ ΑΡΡΥΘΜΙΟΛΟΓΙΚΟ ΣΥΝΕΔΡΙΟ 21-22 ΣΕΠΤΕΜΒΡΙΟΥ 2018 HILTON, ΑΘΗΝΑ Στεφανιαίος ασθενής με μη βαλβιδική Κολπική Μαρμαρυγή - Νέες στρατηγικές Ι. Κανακάκης MD, PhD Διευθυντής Αιμοδυναμικού Τμήματος
A patient with an acute coronary syndrome one year ago. Options for antiplatelet treatment
A patient with an acute coronary syndrome one year ago. Options for antiplatelet treatment Ronen Durst, MD Cardiology Department Hadassah, Hebrew University Medical Center. Chairman, Israeli society for
Razionale ed evidenze scientifiche di Doppia Antiaggregazione Piastrinica a lungo termine nel Paziente con Sindrome Coronarica Acuta
Razionale ed evidenze scientifiche di Doppia Antiaggregazione Piastrinica a lungo termine nel Paziente con Sindrome Coronarica Acuta Giuseppe Musumeci SC Cardiologia Ospedale Santa Croce e Carle Cuneo
A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity
Platelets and Blood Cells 342 A comparative study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity Results of the ISAR-HPR registry Katharina Mayer
What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?
What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation? Keun-Ho Park, Myung Ho Jeong, Min Goo Lee, Jum Suk Ko,
Journal of the American College of Cardiology Vol. 60, No. 3, by the American College of Cardiology Foundation ISSN /$36.
Journal of the American College of Cardiology Vol. 60, No. 3, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.03.050
Understanding the Options Available When Prescribing Dual Antiplatelet Therapy: Dose, Duration, Reversibility, Bleeding Profiles
Understanding the Options Available When Prescribing Dual Antiplatelet Therapy: Dose, Duration, Reversibility, Bleeding Profiles Jessica L. Mega, MD MPH Cardiovascular Division Brigham and Women s Hospital
Simple, Rapid Antiplatelet Therapy Response Assessment
Simple, Rapid Antiplatelet Therapy Response Assessment Acute Care Diagnostics Antiplatelet therapy. Is it working? At least 1 in 3 patients on antiplatelet therapies do not receive the intended physiological
Anti-platelet therapies and dual inhibition in practice
Anti-platelet therapies and dual inhibition in practice Therapeutics; Sept. 25 th 2007 Craig Williams, Pharm.D. Associate Professor of Pharmacy Objectives 1. Understand the pharmacology of thienopyridine
Adjunctive Antithrombotic for PCI. SCAI Fellows Course December 9, 2013
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 9, 2013 Theodore A Bass, MD FSCAI President SCAI Professor of Medicine, University of Florida Medical Director UF Shands CV Center,Jacksonville
POCT in the Management of Antiplatelet Therapy Patient Response, Treatment Optimization and Personalized Medicine
POCT in the Management of Antiplatelet Therapy Patient Response, Treatment Optimization and Personalized Medicine Jackie Coleman, Ph.D. Director of Scientific Affairs Accumetrics, Inc. San Diego, CA Goals
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
Bivalirudin Clinical Trials Update Evidence and Future Perspectives
Bivalirudin Clinical Trials Update Evidence and Future Perspectives Andreas Baumbach Consultant Cardiologist/ hon. Reader in Cardiology Bristol Heart Institute University Hospitals Bristol MY CONFLICTS
Clinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
A new era in the treatment of peripheral artery disease (PAD)?
A new era in the treatment of peripheral artery disease (PAD)? Prof. Dr. Jan Beyer-Westendorf Head of Thrombosis Research, University Hospital Carl Gustav Carus, TU Dresden; Germany Senior Lecturer Thrombosis
Cost is not a barrier to implementing clopidogrel pharmacogenetics. Larisa H. Cavallari, Pharm.D., and Glen T. Schumock, Pharm.D., M.B.A.
Cost is not a barrier to implementing clopidogrel pharmacogenetics Larisa H. Cavallari, Pharm.D., and Glen T. Schumock, Pharm.D., M.B.A. From the Department of Pharmacy Practice (both authors), and the
From STEMIs to Stents: Updates in PCI practice
From STEMIs to Stents: Updates in PCI practice Arnold Seto, MD, MPA Assistant Clinical Professor, UC-Irvine and Long Beach VA Director of Interventional Cardiology Research Hospitalizations in the U.S.
ISCHEMIC HEART DISEASE
ESC CONGRESS HIGHLIGHTS ISCHEMIC HEART DISEASE Francesco Cosentino (Stockholm, S) Declaration of Interest Advisory Board/Speaker: AstraZeneca, Roche, Boehringer-Ingelheim, Bristol-Myers Squibb, Merck,
Update on Oral Antiplatelet Therapy in Coronary Artery Disease
Update on Oral Antiplatelet Therapy in Coronary Artery Disease Ty J. Gluckman, MD, FACC Providence St. Vincent Heart and Vascular Institute, Portland, Oregon Ciccarone Center for the Prevention of Heart
Controversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
Tim Henry, MD Director, Division of Cardiology Professor, Department of Medicine Cedars-Sinai Heart Institute
Tim Henry, MD Director, Division of Cardiology Professor, Department of Medicine Cedars-Sinai Heart Institute Implications of Pre-loading on Patients Undergoing Coronary Angiography Angiography Define
Prasugrel a step ahead in antiplatelet therapy
Prasugrel a step ahead in antiplatelet therapy VS Srinath, MD (Med), DNB (Cardiology) The burden of atherosclerotic disease in the United States and across the world is vast. Although the symptoms of atherosclerosis
What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
Columbia University Medical Center Cardiovascular Research Foundation
STEMI and NSTEMI Pharmacology Confusion: How to Choose and Use Antithrombins (Unfractionated and Low Molecular Heparins, Bivalirudin, Fondaparinux) and Antiplatelet Agents (Aspirin, Clopidogrel and Prasugrel)
No conflict of interest to declare
Switch and Non-Switch in P2Y12 Inhibition: The Real-Life Use of Clopidogrel and Prasugrel in Patients with Acute Myocardial Infarction. Insights from the FAST MI 2010 Registry. F. Schiele (Besançon), E.
QUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.